The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor...
Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinomaPHILADELPHIA, April 17,...
Company leverages proven AI deployment capabilities to accelerate clinical-grade healthcare solutions. MESA, AZ / ACCESS Newswire / April 16, 2026...
AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a clinical-stage...
PITTSBURGH, PA / ACCESS Newswire / April 14, 2026 / The World Tumor Registry ("WTR"), a global non-profit organization with...
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd...
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced...
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and...
Investors and Advisors, and Life Sciences Analysts are Invited to Attend the New York City Event; Virtual Webcast Link Available...
Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The...
Jam in Streets Festival, Headlined by Goose, Attracted 25,000-Plus to AthensAthens, Georgia--(Newsfile Corp. - April 1, 2026) - Athens-based nonprofit...
Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancerPHILADELPHIA, April 01, 2026...
A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous CarcinomasKing of Prussia, Pennsylvania--(Newsfile Corp. - March 30,...
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical...
HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing...
Advances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 Programs PHILADELPHIA, PA / ACCESS...
NEW YORK, March 24, 2026 /PRNewswire/ -- Olatec Therapeutics, Inc. ("Olatec"), developing one of the most clinically advanced specific oral...
AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”),...
Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3...